This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
This Website Uses Cookies By closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
Rarely does a major spending bill in Washington draw bipartisan support and yield immediate results. Behold the CHIPS and Science Act, which was signed into law by President Joe Biden Aug. 9. The act provides more than $52 billion in new funding to boost domestic research and manufacturing of semiconductors in the U.S.
Geopolitical forces are accelerating the growing trends of reshoring and foreign direct investment (FDI). Over the last decade, an expanding understanding of the routine logistics costs of offshoring drove an upward trend of reshoring.
Resilient supply chains are fundamental to our national security and economic prosperity. The pandemic-induced collapse of global supply chains has launched a national movement to strengthen domestic manufacturing.
In his June 2021 editorial, ASSEMBLY's editor in chief John Sprovieri discussed President Biden's February executive order to review critical U.S. supply chains. I would like to build on John's analysis and offer advice to the Biden administration.
Shortening and closing supply chain gaps for essential products will immediately benefit the following industries: personal protective equipment (PPE), medical device manufacturing, electronics and defense. Sixty percent of reshoring cases after March 2020 mention the pandemic as a factor in the decisions. Already, reshoring cases among manufacturers of medical devices and PPE are double compared with last year.
The volatility and uncertainty resulting from trade wars and the COVID-19 pandemic, coupled with increased consumer demand for faster delivery, customization and responsiveness, is helping to promote reshoring and foreign direct investment (FDI) in the United States. Reshoring and FDI are both motivated by the same logic: the agility and financial advantages that companies achieve by producing near their customers.
If there's a silver lining to the COVID pandemic, it might be that it encourages U.S. manufacturers to consider reshoring. Last year's shortages of personal protective equipment, ventilators, pharmaceutical ingredients and other medical products opened a lot of eyes in board rooms and in Washington.
On Demand The past two years have severely strained the global supply chain. Short-term fixes are no longer enough; reshoring assembly is now viable and profitable. Consumer Packaged Goods brands can now control and meet regional demand with agile and digital high-speed assembly.
